Improving T cell therapy to better fight cancer
Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11084456
This study is exploring new ways to make cancer-fighting T cells work better by tweaking their genes, so they can stay strong and effective longer, helping patients get more personalized and powerful treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11084456 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of adoptive T cell therapy (ACT) for cancer treatment by addressing the challenges of T cell exhaustion and the loss of stem cell memory T cells. The team aims to use epigenetic programming to modify T cells, improving their ability to attack cancer cells. By identifying and manipulating specific genes and epigenetic profiles, the research seeks to develop next-generation ACT that can provide more personalized and effective cancer therapies for patients. The approach involves a multidisciplinary team working on advanced technologies to optimize T cell function.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are considering or currently undergoing adoptive T cell therapy.
Not a fit: Patients with non-cancerous conditions or those who do not qualify for T cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the immune system to better target and eliminate cancer cells.
How similar studies have performed: Previous research has shown promise in enhancing T cell therapies through various approaches, making this a potentially impactful continuation of those efforts.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GERSBACH, CHARLES A. — DUKE UNIVERSITY
- Study coordinator: GERSBACH, CHARLES A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy